Ancillary Tests Developed for Salivary Gland Pathology
By LabMedica International staff writers Posted on 03 May 2017 |
Image: An immunohistochemistry of fine needle aspirates in acinic cell carcinoma (AciCC) for SRY-related HMG-box 10 (SOX10) and 2-deoxyglucose-6-phosphate phosphatase (DOG1) (Photo courtesy of Emory University School of Medicine).
Salivary gland tumors represent a diverse set of tumors with a broad range of biologic behaviors, ranging from completely benign tumors to low-grade malignancies to high-grade malignancies.
In addition to this wide range in clinical behavior, salivary gland tumors can show extensive morphologic overlap, so much so that, in many cases, a definitive diagnosis can be impossible without examination of the entire tumor.
Pathologists at the Emory University School of Medicine have examined some of the new advances in salivary gland tumor pathology that have a potential for clinical impact. Ancillary testing with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are improving the ability to make specific diagnoses, or at least to limit the diagnostic consideration on biopsies.
The use of IHC and/or FISH testing can be helpful in the accurate diagnosis of salivary gland tumors in both large resections and, more important, in small biopsy specimens, when combined with clinical information and morphology. These tests are even more useful when applied as part of a panel approach that incorporates tumor morphology to limit the differential diagnosis. Salivary gland tumors also occasionally show targetable molecular alterations, and combined with more-accurate diagnosis, this may allow for more-tailored treatment for the patient and the particular tumor.
Specific tumor types show different frequencies of targetable pathways; therefore, ancillary testing should be tailored to the specific diagnosis. The continuation of clinical work will probably discover more characteristic chromosomal rearrangements, useful antibodies, and targetable mutations in these rare tumors. The study was published in the March 2017 issue of the journal Archives of Pathology & Laboratory Medicine.
In addition to this wide range in clinical behavior, salivary gland tumors can show extensive morphologic overlap, so much so that, in many cases, a definitive diagnosis can be impossible without examination of the entire tumor.
Pathologists at the Emory University School of Medicine have examined some of the new advances in salivary gland tumor pathology that have a potential for clinical impact. Ancillary testing with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are improving the ability to make specific diagnoses, or at least to limit the diagnostic consideration on biopsies.
The use of IHC and/or FISH testing can be helpful in the accurate diagnosis of salivary gland tumors in both large resections and, more important, in small biopsy specimens, when combined with clinical information and morphology. These tests are even more useful when applied as part of a panel approach that incorporates tumor morphology to limit the differential diagnosis. Salivary gland tumors also occasionally show targetable molecular alterations, and combined with more-accurate diagnosis, this may allow for more-tailored treatment for the patient and the particular tumor.
Specific tumor types show different frequencies of targetable pathways; therefore, ancillary testing should be tailored to the specific diagnosis. The continuation of clinical work will probably discover more characteristic chromosomal rearrangements, useful antibodies, and targetable mutations in these rare tumors. The study was published in the March 2017 issue of the journal Archives of Pathology & Laboratory Medicine.
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form